Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD, on Results of the PALOMA3 Study on Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer
2015 ASCO Annual Meeting
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discuss fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed on prior endocrine therapy (Abstract LBA502).
Related Videos
Christian Carrie, MD and Celestia S. Higano, MD
Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).
Saad Usmani, MD
For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show promise in multiple myeloma (Abstract LBA8512).
Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD
Lisa Diller, MD, of Dana-Farber Cancer Institute, and Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discuss the findings of a landmark survivorship study (Abstract LBA2).
Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM
Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).
